Tetracycline: Doxycycline analog

PreclinicalSmall molecule

UUniversity of Texas Southwestern Medical Center

Tetracycline: Doxycycline analog is one of 11 small molecule programs targeting Blepharitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlepharitisActive, not recruiting

BlepharitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Blepharitis

#DrugCompanyPhaseTrials

E-Mycin

AAzurity Pharmaceuticals

Approved

1 2

Tobrex

VViatris Specialty LLC

Levaquin

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Flagyl

Elidel

BBausch Health Americas, Inc.

Lotemax

1 8

Xdemvy

TTarsus Pharmaceuticals, Inc.

Approved

1 9

NATACYN

IIVIEW Therapeutics Inc.

Phase 3

1 10

Betadine

BBecton, Dickinson and Company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blepharitis1 trial

A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease

Withdrawn·UUniversity of Texas Southwestern Medical Center·N/A·NCT00355459

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tetracycline: Doxycycline analog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetracycline: Doxycycline analog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetracycline: Doxycycline analog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Texas Southwestern Medical Center

Tetracycline: Doxycycline analog

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blepharitis1 trial

References

Drug Info

Quick Facts

Related News